person · Reporting owner

Naftzger J. Christopher

Disclosed activity across 2 companies

Tapewire entity: 83058
SEC CIK: 0001496194

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Arbutus Biopharma CorpABUS · Entity 4953	General Counsel and CCO	February 14, 2025	February 19, 2025
Nabriva Therapeutics plcNBRV · Entity 111497	General Counsel and Corp Sec	August 11, 2022	August 15, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Arbutus Biopharma Corp

Report date February 14, 2025 · Filed February 19, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	140,544	Reported balance After 2025-02-14 transaction · row 1 1 source row Row 1 · 2025-02-14 · Grant · Acquired 54,300 · Balance 140,544 F1: Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.29 · Expires 2035-02-14	Direct	220,300	Reported balance After 2025-02-14 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-02-14 · Grant · Acquired 220,300 · Balance 220,300 F2: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. F3: This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction.

F2: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant.

F3: This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date.

Nabriva Therapeutics plc

Report date August 11, 2022 · Filed August 15, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.45 · Expires 2032-01-27	Direct	0	Reported balance After 2022-08-11 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-08-11 · Exercise / conversion · Disposed 63,200 · Balance 0 F1: The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 Annual General Meeting (the "2022 AGM") of Nabriva Therapeutics plc (the "Issuer"), the option would remain outstanding and convert into a cash-settled share appreciation right. On August 11, 2022, the Issuer held the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the option to convert to a cash-settled share appreciation right. F2: Subject to the reporting person's continued employment with the Issuer, the cash-settled share appreciation right will vest over a four-year period beginning January 28, 2023. Twenty-five percent (25%) of the cash-settled share appreciation right will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the cash-settled share appreciation right will vest on a monthly pro-rata basis over the remaining vesting period.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2022-08-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2022-08-11 · Exercise / conversion · Disposed 31,600 · Balance 0 F3: The restricted stock units ("RSU") were granted on January 28, 2022, and each RSU represented a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 AGM, then each RSU would represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date ( "Phantom Shares"). On August 11, 2022, the Issuer held it's the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the RSU to convert to Phantom Shares. F4: Subject to the reporting person's continued employment with the Issuer, the Phantom Shares will vest in equal annual installments over four years with the first installment vesting on January 28, 2023.
Stock Appreciation RightSEC Table II · derivative / convertible security · Conversion / exercise price $0.45 · Expires 2032-01-27	Direct	63,200	Reported balance After 2022-08-11 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-08-11 · Exercise / conversion · Acquired 63,200 · Balance 63,200 F1: The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 Annual General Meeting (the "2022 AGM") of Nabriva Therapeutics plc (the "Issuer"), the option would remain outstanding and convert into a cash-settled share appreciation right. On August 11, 2022, the Issuer held the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the option to convert to a cash-settled share appreciation right. F2: Subject to the reporting person's continued employment with the Issuer, the cash-settled share appreciation right will vest over a four-year period beginning January 28, 2023. Twenty-five percent (25%) of the cash-settled share appreciation right will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the cash-settled share appreciation right will vest on a monthly pro-rata basis over the remaining vesting period.
Phantom SharesSEC Table II · derivative / convertible security	Direct	31,600	Reported balance After 2022-08-11 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-08-11 · Exercise / conversion · Acquired 31,600 · Balance 31,600 F3: The restricted stock units ("RSU") were granted on January 28, 2022, and each RSU represented a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 AGM, then each RSU would represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date ( "Phantom Shares"). On August 11, 2022, the Issuer held it's the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the RSU to convert to Phantom Shares. F4: Subject to the reporting person's continued employment with the Issuer, the Phantom Shares will vest in equal annual installments over four years with the first installment vesting on January 28, 2023.

Filing footnotes · ownership attribution and instrument terms

F1: The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 Annual General Meeting (the "2022 AGM") of Nabriva Therapeutics plc (the "Issuer"), the option would remain outstanding and convert into a cash-settled share appreciation right. On August 11, 2022, the Issuer held the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the option to convert to a cash-settled share appreciation right.

F2: Subject to the reporting person's continued employment with the Issuer, the cash-settled share appreciation right will vest over a four-year period beginning January 28, 2023. Twenty-five percent (25%) of the cash-settled share appreciation right will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the cash-settled share appreciation right will vest on a monthly pro-rata basis over the remaining vesting period.

F3: The restricted stock units ("RSU") were granted on January 28, 2022, and each RSU represented a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 AGM, then each RSU would represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date ( "Phantom Shares"). On August 11, 2022, the Issuer held it's the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the RSU to convert to Phantom Shares.

F4: Subject to the reporting person's continued employment with the Issuer, the Phantom Shares will vest in equal annual installments over four years with the first installment vesting on January 28, 2023.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 14, 2025 Filed Feb 19, 2025 18:25 UTC	Arbutus Biopharma Corp ABUS · Entity 4953	GrantStock Option (Right to Buy) · Derivative	220,300	$0.00 Strike: $3.29	$0.00	Disclosure SEC source: 0001447028-25-000052 · wk-form4_1740007544.xml · derivative · entry 2 Naftzger J. Christopher · CIK 0001496194 · General Counsel and CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,300 Underlying: Common Shares · 220,300 shares Expires 2035-02-14 F2 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. F3 · derivative.exercise_date: This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document
February 14, 2025 Filed Feb 19, 2025 18:25 UTC	Arbutus Biopharma Corp ABUS · Entity 4953	GrantCommon Shares	54,300	$0.00	$0.00	Disclosure SEC source: 0001447028-25-000052 · wk-form4_1740007544.xml · nonDerivative · entry 1 Naftzger J. Christopher · CIK 0001496194 · General Counsel and CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,544 F1 · shares: Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction. Read SEC document
February 04, 2025 Filed Feb 5, 2025 16:02 UTC	Arbutus Biopharma Corp ABUS · Entity 4953	SaleCommon Shares	11,333	$3.28	$37,206.24	Disclosure SEC source: 0001447028-25-000037 · wk-form4_1738789328.xml · nonDerivative · entry 1 Naftzger J. Christopher · CIK 0001496194 · General Counsel and CCO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,244 F1 · kind: Represents the non-discretionary sale of common shares pursuant to the Reporting Person's 10b5-1 Plan, adopted on July 11, 2023, to satisfy the Reporting Person's tax obligations with respect to the vesting of previous grants of restricted stock units. F2 · balance_after: Includes 1,214 and 1,263 shares acquired under the Arbutus Biopharma Corporation 2020 Employee Stock Purchase Plan on February 29, 2024 and August 30, 2024, respectively. Read SEC document
February 01, 2024 Filed Feb 5, 2024 19:55 UTC	Arbutus Biopharma Corp ABUS · Entity 4953	GrantStock Option (Right to Buy) · Derivative	380,500	$0.00 Strike: $2.40	$0.00	Disclosure SEC source: 0001447028-24-000029 · wk-form4_1707180904.xml · derivative · entry 2 Naftzger J. Christopher · CIK 0001496194 · General Counsel and CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 380,500 Underlying: Common Shares · 380,500 shares Expires 2034-02-01 F2 · derivative.exercise_price: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. F3 · derivative.exercise_date: This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document
February 01, 2024 Filed Feb 5, 2024 19:55 UTC	Arbutus Biopharma Corp ABUS · Entity 4953	GrantCommon Shares	95,100	$0.00	$0.00	Disclosure SEC source: 0001447028-24-000029 · wk-form4_1707180904.xml · nonDerivative · entry 1 Naftzger J. Christopher · CIK 0001496194 · General Counsel and CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,100 F1 · shares: Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction. Read SEC document
July 10, 2023 Filed Jul 12, 2023 16:12 UTC	Arbutus Biopharma Corp ABUS · Entity 4953	GrantStock Option (Right to Buy) · Derivative	500,000	$0.00 Strike: $2.26	$0.00	Disclosure SEC source: 0001447028-23-000066 · wk-form4_1689192740.xml · derivative · entry 1 Naftzger J. Christopher · CIK 0001496194 · General Counsel and CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Shares · 500,000 shares Expires 2033-07-10 F1 · derivative.exercise_price: Reflects the closing price of the Issuer's common shares on the Nasdaq Stock Market on July 10, 2023, the date of the grant. F2 · derivative.exercise_date: This option shall vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document
August 11, 2022 Filed Aug 15, 2022 20:39 UTC	Nabriva Therapeutics plc NBRV · Entity 111497	Exercise / conversionPhantom Shares · Derivative	31,600	$0.00	$0.00	Disclosure SEC source: 0001104659-22-091488 · tm2222534-17_4seq1.xml · derivative · entry 4 Naftzger J. Christopher · CIK 0001496194 · General Counsel and Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,600 Underlying: Ordinary Shares · 31,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The restricted stock units ("RSU") were granted on January 28, 2022, and each RSU represented a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 AGM, then each RSU would represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date ( "Phantom Shares"). On August 11, 2022, the Issuer held it's the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the RSU to convert to Phantom Shares. F3 · date: The restricted stock units ("RSU") were granted on January 28, 2022, and each RSU represented a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 AGM, then each RSU would represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date ( "Phantom Shares"). On August 11, 2022, the Issuer held it's the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the RSU to convert to Phantom Shares. F4 · derivative.exercise_date: Subject to the reporting person's continued employment with the Issuer, the Phantom Shares will vest in equal annual installments over four years with the first installment vesting on January 28, 2023. F4 · derivative.expiration_date: Subject to the reporting person's continued employment with the Issuer, the Phantom Shares will vest in equal annual installments over four years with the first installment vesting on January 28, 2023. F3 · derivative.underlying_shares: The restricted stock units ("RSU") were granted on January 28, 2022, and each RSU represented a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 AGM, then each RSU would represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date ( "Phantom Shares"). On August 11, 2022, the Issuer held it's the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the RSU to convert to Phantom Shares. F3 · balance_after: The restricted stock units ("RSU") were granted on January 28, 2022, and each RSU represented a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 AGM, then each RSU would represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date ( "Phantom Shares"). On August 11, 2022, the Issuer held it's the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the RSU to convert to Phantom Shares. Read SEC document
August 11, 2022 Filed Aug 15, 2022 20:39 UTC	Nabriva Therapeutics plc NBRV · Entity 111497	Exercise / conversionStock Appreciation Right · Derivative	63,200	$0.00 Strike: $0.45	$0.00	Disclosure SEC source: 0001104659-22-091488 · tm2222534-17_4seq1.xml · derivative · entry 3 Naftzger J. Christopher · CIK 0001496194 · General Counsel and Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,200 Underlying: Ordinary Shares · 63,200 shares Expires 2032-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 Annual General Meeting (the "2022 AGM") of Nabriva Therapeutics plc (the "Issuer"), the option would remain outstanding and convert into a cash-settled share appreciation right. On August 11, 2022, the Issuer held the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the option to convert to a cash-settled share appreciation right. F1 · derivative.exercise_date: The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 Annual General Meeting (the "2022 AGM") of Nabriva Therapeutics plc (the "Issuer"), the option would remain outstanding and convert into a cash-settled share appreciation right. On August 11, 2022, the Issuer held the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the option to convert to a cash-settled share appreciation right. F2 · derivative.exercise_date: Subject to the reporting person's continued employment with the Issuer, the cash-settled share appreciation right will vest over a four-year period beginning January 28, 2023. Twenty-five percent (25%) of the cash-settled share appreciation right will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the cash-settled share appreciation right will vest on a monthly pro-rata basis over the remaining vesting period. F1 · derivative.underlying_shares: The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 Annual General Meeting (the "2022 AGM") of Nabriva Therapeutics plc (the "Issuer"), the option would remain outstanding and convert into a cash-settled share appreciation right. On August 11, 2022, the Issuer held the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the option to convert to a cash-settled share appreciation right. F1 · balance_after: The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 Annual General Meeting (the "2022 AGM") of Nabriva Therapeutics plc (the "Issuer"), the option would remain outstanding and convert into a cash-settled share appreciation right. On August 11, 2022, the Issuer held the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the option to convert to a cash-settled share appreciation right. Read SEC document
August 11, 2022 Filed Aug 15, 2022 20:39 UTC	Nabriva Therapeutics plc NBRV · Entity 111497	Exercise / conversionRestricted Stock Units · Derivative	31,600	$0.00	$0.00	Disclosure SEC source: 0001104659-22-091488 · tm2222534-17_4seq1.xml · derivative · entry 2 Naftzger J. Christopher · CIK 0001496194 · General Counsel and Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 31,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The restricted stock units ("RSU") were granted on January 28, 2022, and each RSU represented a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 AGM, then each RSU would represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date ( "Phantom Shares"). On August 11, 2022, the Issuer held it's the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the RSU to convert to Phantom Shares. F3 · date: The restricted stock units ("RSU") were granted on January 28, 2022, and each RSU represented a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 AGM, then each RSU would represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date ( "Phantom Shares"). On August 11, 2022, the Issuer held it's the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the RSU to convert to Phantom Shares. F4 · derivative.exercise_date: Subject to the reporting person's continued employment with the Issuer, the Phantom Shares will vest in equal annual installments over four years with the first installment vesting on January 28, 2023. F4 · derivative.expiration_date: Subject to the reporting person's continued employment with the Issuer, the Phantom Shares will vest in equal annual installments over four years with the first installment vesting on January 28, 2023. F3 · derivative.underlying_shares: The restricted stock units ("RSU") were granted on January 28, 2022, and each RSU represented a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 AGM, then each RSU would represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date ( "Phantom Shares"). On August 11, 2022, the Issuer held it's the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the RSU to convert to Phantom Shares. F3 · balance_after: The restricted stock units ("RSU") were granted on January 28, 2022, and each RSU represented a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 AGM, then each RSU would represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date ( "Phantom Shares"). On August 11, 2022, the Issuer held it's the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the RSU to convert to Phantom Shares. Read SEC document
August 11, 2022 Filed Aug 15, 2022 20:39 UTC	Nabriva Therapeutics plc NBRV · Entity 111497	Exercise / conversionShare Options · Derivative	63,200	$0.00 Strike: $0.45	$0.00	Disclosure SEC source: 0001104659-22-091488 · tm2222534-17_4seq1.xml · derivative · entry 1 Naftzger J. Christopher · CIK 0001496194 · General Counsel and Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 63,200 shares Expires 2032-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 Annual General Meeting (the "2022 AGM") of Nabriva Therapeutics plc (the "Issuer"), the option would remain outstanding and convert into a cash-settled share appreciation right. On August 11, 2022, the Issuer held the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the option to convert to a cash-settled share appreciation right. F1 · derivative.exercise_date: The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 Annual General Meeting (the "2022 AGM") of Nabriva Therapeutics plc (the "Issuer"), the option would remain outstanding and convert into a cash-settled share appreciation right. On August 11, 2022, the Issuer held the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the option to convert to a cash-settled share appreciation right. F2 · derivative.exercise_date: Subject to the reporting person's continued employment with the Issuer, the cash-settled share appreciation right will vest over a four-year period beginning January 28, 2023. Twenty-five percent (25%) of the cash-settled share appreciation right will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the cash-settled share appreciation right will vest on a monthly pro-rata basis over the remaining vesting period. F1 · derivative.underlying_shares: The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 Annual General Meeting (the "2022 AGM") of Nabriva Therapeutics plc (the "Issuer"), the option would remain outstanding and convert into a cash-settled share appreciation right. On August 11, 2022, the Issuer held the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the option to convert to a cash-settled share appreciation right. F1 · balance_after: The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 Annual General Meeting (the "2022 AGM") of Nabriva Therapeutics plc (the "Issuer"), the option would remain outstanding and convert into a cash-settled share appreciation right. On August 11, 2022, the Issuer held the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the option to convert to a cash-settled share appreciation right. Read SEC document
January 28, 2022 Filed Feb 1, 2022 18:35 UTC	Nabriva Therapeutics plc NBRV · Entity 111497	GrantRestricted Stock Units · Derivative	31,600	$0.00	$0.00	Disclosure SEC source: 0001104659-22-010484 · tm221371-7_4seq1.xml · derivative · entry 2 Naftzger J. Christopher · CIK 0001496194 · General Counsel and Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,600 Underlying: Ordinary Shares · 31,600 shares Expires not disclosed F3 · derivative.exercise_price: The restricted stock units ("RSU") were granted on January 28, 2022, and each RSU represents a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval is not obtained, then each RSU will represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date. F3 · date: The restricted stock units ("RSU") were granted on January 28, 2022, and each RSU represents a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval is not obtained, then each RSU will represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date. F4 · derivative.exercise_date: Subject to the reporting person's continued employment with the Issuer, the RSUs will vest in equal annual installments over four years with the first installment vesting on January 28, 2023. F4 · derivative.expiration_date: Subject to the reporting person's continued employment with the Issuer, the RSUs will vest in equal annual installments over four years with the first installment vesting on January 28, 2023. F3 · derivative.underlying_shares: The restricted stock units ("RSU") were granted on January 28, 2022, and each RSU represents a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval is not obtained, then each RSU will represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date. F3 · balance_after: The restricted stock units ("RSU") were granted on January 28, 2022, and each RSU represents a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval is not obtained, then each RSU will represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date. Read SEC document
January 28, 2022 Filed Feb 1, 2022 18:35 UTC	Nabriva Therapeutics plc NBRV · Entity 111497	GrantShare Options · Derivative	63,200	$0.00 Strike: $0.45	$0.00	Disclosure SEC source: 0001104659-22-010484 · tm221371-7_4seq1.xml · derivative · entry 1 Naftzger J. Christopher · CIK 0001496194 · General Counsel and Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,200 Underlying: Ordinary Shares · 63,200 shares Expires 2032-01-27 F1 · date: The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval is not obtained, the option will remain outstanding and convert into a cash-settled share appreciation right. F2 · derivative.exercise_date: Subject to the reporting person's continued employment with Nabriva Therapeutics plc (the "Issuer"), the option will vest over a four-year period beginning January 28, 2023. Twenty-five percent (25%) of the option will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the option will vest on a monthly pro-rata basis over the remaining vesting period. F1 · derivative.underlying_shares: The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval is not obtained, the option will remain outstanding and convert into a cash-settled share appreciation right. F1 · balance_after: The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval is not obtained, the option will remain outstanding and convert into a cash-settled share appreciation right. Read SEC document
December 27, 2021 Filed Dec 28, 2021 19:04 UTC	Nabriva Therapeutics plc NBRV · Entity 111497	PurchaseOrdinary Shares	7,000	$0.59	$4,130.00	Disclosure SEC source: 0001104659-21-154012 · tm2136401-1_4seq1.xml · nonDerivative · entry 1 Naftzger J. Christopher · CIK 0001496194 · General Counsel and Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Read SEC document
September 30, 2021 Filed Oct 1, 2021 16:06 UTC	Nabriva Therapeutics plc NBRV · Entity 111497	GrantShare Option · Derivative	100,000	$0.00 Strike: $1.19	$0.00	Disclosure SEC source: 0001104659-21-121964 · tm2129004-1_4seq1.xml · derivative · entry 1 Naftzger J. Christopher · CIK 0001496194 · General Counsel and Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Ordinary Shares · 100,000 shares Expires 2031-09-29 F1 · date: The option was granted on September 30, 2021. F2 · derivative.exercise_date: The option will vest over a four-year period. Twenty-five percent (25%) of the option will vest on the one (1)-year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the option will vest on an annual pro-rata basis over the remaining vesting period. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.